CHLZT is mainly involved in the IL-17 signaling pathway, AGE-RAGE signaling pathway in diabetes complications, protease binding, and cofactor binding, and finally plays a potential regulatory mechanism for NAFLD. This evidence concerns the gene RENBP and metabolic dysfunction-associated steatotic liver disease.